合并自身免疫性疾病的黑色素瘤患者的免疫疗法

doi:10.3760/cma.j.issn.1673-422X.2017.04.019

摘要/Abstract

摘要： 免疫疗法已经成为黑色素瘤治疗的重要手段。抗细胞毒T淋巴细胞相关抗原-4（cytotoxic T lymphocyte-associated antigen-4,CTLA-4）抗体或程序性死亡受体-1(programmed death-1,PD-1)/程序性死亡-配体1(programmed death-ligand 1,PD-L1)抑制剂用于治疗合并自身免疫性疾病（AD）的黑色素瘤安全有效。尽管如此，当此类患者应用抗CTLA-4抗体或PD-1/PD-L1时，仍应密切观察其病情变化，以预防和避免可能出现的AD进展和免疫相关不良反应。

关键词: 黑色素瘤, 免疫疗法, 自身免疫性疾病

Abstract: Immunotherapy has become an important treatment for melanoma. The anti-cytotoxic T lymphocyte-associated antigen-4 (CTLA-4） antibody or programmed death-1 (PD-1)/programmed deathligand 1 (PD-L1) inhibitor is safe and effective for melanoma patients with autoimmune disease (AD). However, when such patients are treated with anti-CTLA-4 antibody or PD-1/PD-L1 inhibitors, their condition changes should be closely monitored to prevent and avoid possible AD progression and immune-related adverse events.

Key words: Melanoma, Immunotherapy, Autoimmune disease

孙澄宇,徐玉清. 合并自身免疫性疾病的黑色素瘤患者的免疫疗法[J]. 国际肿瘤学杂志, 2017, 44(4): 310-312.

Sun Chengyu, Xu Yuqing. Immunotherapy in melanoma patients with autoimmune disease[J]. Journal of International Oncology, 2017, 44(4): 310-312.

参考文献

［1］ Bertrand A, Kostine M, Barnetche T, et al. Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis［J］. BMC Med, 2015, 13: 211. DOI: 10.1186/s12916-015-0455-8. ［2］ Franks AL, Slansky JE. Multiple associations between a broad spectrum of autoimmune diseases, chronic inflammatory diseases and cancer［J］. Anticancer Res, 2012, 32(4): 11191136. ［3］ Lopez-Olivo MA, Tayar JH, MartinezLopez JA, et al. Risk of malignancies in patients with rheumatoid arthritis treated with biologic therapy: a meta-analysis［J］. JAMA, 2012, 308(9): 898-908. DOI: 10.1001/2012.jama.10857. ［4］ Raaschou P, Simard JF, Holmqvist M, et al. Rheumatoid arthritis, anti-tumour necrosis factor therapy, and risk of malignant melanoma: nationwide population based prospective cohort study from Sweden［J］. BMJ, 2013, 346: f1939. DOI: 10.1136/bmj.f1939. ［5］ Walker LS, Sansom DM. Confusing signals: recent progress in CTLA-4 biology［J］. Trends Immunol, 2015, 36(2): 63-70. DOI: 10.1016/j.it.2014.12.001. ［6］ Hall CJ, Doss S, Robertson J, et al. NICE guidance on ipilimumab for treating previously untreated advanced (unresectable or metastatic) melanoma［J］. Lancet Oncol, 2014, 15(10): 1056-1057.. ［7］ Hodi FS, O′Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma［J］. N Engl J Med, 2010, 363(8): 711-723. DOI: 10.1056/NEJMoa1003466. ［8］ Kyi C, Carvajal RD, Wolchok JD, et al. Ipilimumab in patients with melanoma and autoimmune disease［J］. J Immunother Cancer, 2013, 2(1): 35. DOI: 10.1186/s40425-014-0035-z. ［9］ Lee B, Wong A, Kee D, et al. The use of ipilimumab in patients with rheumatoid arthritis and metastatic melanoma［J］. Ann Oncol, 2016, 27(6): 1174-1177. DOI: 10.1093/annonc/mdw056. ［10］ Pedersen M, Andersen R, N-rgaard P, et al. Successful treatment with ipilimumab and interleukin-2 in two patients with metastatic melanoma and systemic autoimmune disease［J］. Cancer Immunol Immunother, 2014, 63(12): 1341-1346. DOI: 10.1007/s00262-014-1607-y. ［11］ Gettings EJ, Hackett CT, Scott TF. Severe relapse in a multiple sclerosis patient associated with ipilimumab treatment of melanoma［J］. Mult Scler, 2015, 21(5): 670. DOI: 10.1177/1352458514549403. ［12］ Johnson DB, Sullivan RJ, Ott PA, et al. Ipilimumab therapy in patients with advanced melanoma and preexisting autoimmune disorders［J］. JAMA Oncol, 2016, 2(2): 234-240. DOI: 10.1001/jamaoncol.2015.4368. ［13］ Borch TH, Donia M, Andersen MH, et al. Reorienting the immune system in the treatment of cancer by using anti-PD-1 and anti-PD-L1 antibodies［J］. Drug Discov Today, 2015, 20(9): 1127-1134. DOI: 10.1016/j.drudis.2015.07.003. ［14］ Spranger S, Spaapen RM, Zha Y, et al. Upregulation of PD-L1, IDO, and T (regs) in the melanoma tumor microenvironment is driven by CD8 (+) T cells［J］. Sci Transl Med, 2013, 5(200): 200ra116. DOI: 10.1126/scitranslmed.3006504. ［15］ Tumeh PC, Harview CL, Yearley JH, et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance［J］. Nature, 2014, 515(7528): 568-571. DOI: 10.1038/nature13954. ［16］ Robert C, Schachter J, Long GV, et al. Pembrolizumab versus ipilimumab in advanced melanoma［J］. N Engl J Med, 2015, 372(26): 2521-2532. DOI: 10.1056/NEJMoa1503093. ［17］ Postow MA, Callahan MK, Wolchok JD. Immune checkpoint blo-ckade in cancer therapy［J］. J Clin Oncol, 2015, 33(17): 1974-1982. DOI: 10.1200/JCO.2014.59.4358. ［18］ Beck KM, Dong J, Geskin LJ, et al. Disease stabilization with pembrolizumab for metastatic acral melanoma in the setting of autoimmune bullous pemphigoid［J］. J Immunother Cancer, 2016, 4: 20. DOI: 10.1186/s40425-016-0123-3. ［19］ Menzies AM, Johnson DB, Ramanujam S, et al. Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab［J］. Ann Oncol, 2016, pii: mdw443. DOI: 10.1093/annonc/mdw443.

[1]	高凡, 王萍, 杜超, 褚衍六. 肠道菌群与结直肠癌非手术治疗的相关研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 376-381.
[2]	范志鹏, 余静, 胡静, 廖正凯, 徐禹, 欧阳雯, 谢丛华. 炎症标志物的变化趋势对一线接受免疫联合化疗的晚期非小细胞肺癌患者预后的预测价值[J]. 国际肿瘤学杂志, 2024, 51(5): 257-266.
[3]	张文馨, 夏泠, 彭晋, 周福祥. 甲胎蛋白升高型胃肝样腺癌1例并文献复习[J]. 国际肿瘤学杂志, 2024, 51(5): 312-315.
[4]	杨毫, 施贵冬, 张程城, 张跃, 张力文, 付茂勇. 信迪利单抗与替雷利珠单抗在进展期食管鳞状细胞癌新辅助治疗中的疗效及安全性对比[J]. 国际肿瘤学杂志, 2024, 51(4): 210-216.
[5]	萨蔷, 徐航程, 王佳玉. 乳腺癌免疫治疗研究进展[J]. 国际肿瘤学杂志, 2024, 51(4): 227-234.
[6]	张栋岩, 王品, 魏秋亚, 邓成伍, 魏相相, 高远飞, 王琛. 索凡替尼靶向联合卡培他滨和奥沙利铂治疗肝内胆管癌术后患者1例及文献复习[J]. 国际肿瘤学杂志, 2024, 51(4): 249-253.
[7]	孙维蔚, 姚学敏, 王鹏健, 王静, 贾敬好. 基于血液学指标探讨免疫治疗晚期非小细胞肺癌预后因素及列线图构建[J]. 国际肿瘤学杂志, 2024, 51(3): 143-150.
[8]	刘玉兰, 井海燕, 孙静, 宋伟, 沙丹. 胃癌免疫治疗疗效预测及预后标志物的研究进展[J]. 国际肿瘤学杂志, 2024, 51(3): 175-180.
[9]	崔腾璐, 吕璐, 孙鹏飞. 放疗联合免疫治疗在头颈部鳞状细胞癌治疗中的应用[J]. 国际肿瘤学杂志, 2023, 50(9): 548-552.
[10]	李开春, 丁昌利, 于文艳. 安罗替尼联合特瑞普利单抗治疗晚期肺肉瘤样癌1例[J]. 国际肿瘤学杂志, 2023, 50(8): 511-512.
[11]	吴旻杭, 孙文政, 于庆卓, 郭蓉, 叶辉, 杜莹, 邱晋, 安华章, 曹莉莉. RNF43通过β-catenin抑制黑色素瘤细胞PD-L1表达并促进CD8⁺T细胞介导的抗肿瘤免疫反应[J]. 国际肿瘤学杂志, 2023, 50(7): 407-412.
[12]	过慈良, 江春平, 吴俊华. 肠道菌群与肿瘤免疫治疗[J]. 国际肿瘤学杂志, 2023, 50(7): 432-436.
[13]	陈秋, 王雷, 王明琦, 张梅. 恩沃利单抗联合阿昔替尼治疗肾癌肺转移1例并文献复习[J]. 国际肿瘤学杂志, 2023, 50(7): 445-448.
[14]	李青珊, 谢鑫, 张楠, 刘帅. 放疗联合系统治疗在乳腺癌中的应用进展[J]. 国际肿瘤学杂志, 2023, 50(6): 362-367.
[15]	顾安琴, 龙金华, 金风. 鼻咽癌免疫治疗的临床研究进展[J]. 国际肿瘤学杂志, 2023, 50(5): 299-303.